Drug Trial Radar · NCT04629729
FT819 in Subjects With B-cell Malignancies
Last checked: Nov 19, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
54
Actual
Start
Jul 12, 2021
Primary completion
Jun 18, 2025
Study completion Sep 30, 2039
Sponsor
- Lead sponsor
- Fate TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Conditions
- Lymphoma, B-Cell
- Chronic Lymphocytic Leukemia
- Precursor B-Cell Acute Lymphoblastic Leukemia
Interventions
FT819Drug
Experimental Interventional Therapy
CyclophosphamideDrug
Lympho-conditioning agent
FludarabineDrug
Lympho-conditioning agent
IL-2Drug
Biologic response modifier
BendamustineDrug
Lympho-conditioning agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and nature of dose-limiting toxicities within each dose level cohortTime frame: Up to Day 29
- Incidence, nature, and severity of adverse events (AEs) of FT819 as monotherapy and in combination with IL-2 in r/r B-cell lymphoma, r/r chronic lymphocytic leukemia, and r/r precursor B-cell acute lymphoblastic leukemiaTime frame: Up to 15 years
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Mayo Arizona
Phoenix, Arizona
UC Davis
Davis, California
Scripps Green Hospital
La Jolla, California
UCLA Ronald Reagan Medical Center
Los Angeles, California
Stanford Cancer Institute
Palo Alto, California
University of Florida
Gainesville, Florida
Mayo Florida
Jacksonville, Florida
University of Iowa
Iowa City, Iowa
The University of Kansas Cancer Center
Westwood, Kansas
Norton Cancer Institute, St. Matthews Campus
Louisville, Kentucky
Mayo Minnesota
Rochester, Minnesota
University of Nebraska Medical Center
Omaha, Nebraska
Hackensack University Medical Center
Hackensack, New Jersey
Memorial Sloan Kettering Cancer Center
New York, New York
Oregon Health & Sciences University
Portland, Oregon
MD Anderson Cancer Center
Houston, Texas
University of Wisconsin-Madison
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.